MedTrace Logo

Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions

NCT03486327 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-08-23

Study results available
· View outcomes & findings →

Summary

This is an exploratory, single center, open label, parallel-dose, and prospective study of BR55 contrast-enhanced ultrasonography (CEUS) for characterization of solid pancreatic lesions in subjects with suspected pancreatic ductal adenocarcinoma (PDAC) using transabdominal US.

Conditions

Interventions

DRUG

BR55

A novel targeted ultrasound contrast agent

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Maria Luigia Storto, MD · Bracco Diagnostics, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2020-11-13
Completion
2021-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03486327 on ClinicalTrials.gov